R Venkataramanan

R Venkataramanan

R Venkat's Blog

R Venkat's Blog
"To be an Inspiring Teacher,one should be a Disciplined Student throughout Life" - Venkataramanan Ramasethu

SNK

SNK

Sunday, February 24, 2013

Retinopathy

Retinopathy is due to persistent or acute damage to the retina of the eye. Ongoing inflammation and vascular remodeling may occur over periods of time where the patient is not fully aware of the extent of the disease. Frequently, retinopathy is an ocular manifestation of systemic disease as seen in diabetes or hypertension.[1]

Causes of retinopathy include but not limited to:
Diabetes mellitus, which causes diabetic retinopathy
Arterial hypertension, which causes hypertensive retinopathy
Retinopathy of prematurity due to prematurity of the newborn (under the 9 months of human pregnancy).
Radiation retinopathy due to exposure to ionizing radiation.
Solar retinopathy due to direct sunlight exposure.
Sickle cell disease
Retinal vascular disease such as retinal vein or artery occlusion.
Trauma, especially to the head, and several diseases may cause Purtscher's retinopathy
Hyperviscosity-related retinopathy as seen in disorders which cause paraproteinemia
Many types of retinopathy are proliferative resulting, most often, from neovascularization or the overgrowth of blood vessels. Angiogenesis, the sprouting of new vessels is the hallmark precursor that may result in blindness or severe vision loss particularly if the macula becomes affected.[1]
Retinopathy may rarely due to genetic diseases such as retinitis pigmentosa. ciliopathy is another rare cause.[2]
Retinopathy is diagnosed by an ophthalmologist during eye examination. Treatment depends on the cause of the disease.

Treatment is based on the cause of the retinopathy and may include laser therapy to the retina. In recent years targeting the pathway controlling vessel growth or angiogenesis has been promising. Vascular endothelial growth factor (VEGF) seems to play a vital role in promoting neovascularization. Using anti-VEGF drugs (antibodies to sequester the growth factor), researches have shown significant reduction in the extent of vessel outgrowth. Several anti-VEGF treatments are currently under review in both clinical trials and in preclinical labs